STOK
Income statement / Annual
Last year (2024), Stoke Therapeutics, Inc.'s total revenue was $36.56 M,
an increase of 316.34% from the previous year.
In 2024, Stoke Therapeutics, Inc.'s net income was -$88.98 M.
See Stoke Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$36.56 M |
$8.78 M |
$12.41 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.93 M
|
$450.00 K
|
$214.00 K
|
$113.00 K
|
| Gross Profit |
$36.56 M
|
$8.78 M
|
$12.41 M
|
$0.00
|
-$1.93 M
|
-$450.00 K
|
-$214.00 K
|
-$113.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$89.13 M
|
$82.23 M
|
$77.84 M
|
$54.17 M
|
$32.20 M
|
$23.31 M
|
$8.37 M
|
$3.60 M
|
| General & Administrative Expenses |
$48.79 M
|
$41.32 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$0.00
|
$4.41 M
|
$1.96 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$48.79 M
|
$41.32 M
|
$38.92 M
|
$31.90 M
|
$20.85 M
|
$11.91 M
|
$4.41 M
|
$1.96 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.93 M
|
$0.00
|
-$10.00 K
|
-$4.00 K
|
| Operating Expenses |
$137.93 M
|
$123.55 M
|
$116.76 M
|
$86.07 M
|
$51.12 M
|
$35.23 M
|
$12.78 M
|
$5.55 M
|
| Cost And Expenses |
$137.93 M
|
$123.55 M
|
$116.76 M
|
$86.07 M
|
$53.04 M
|
$35.68 M
|
$12.78 M
|
$5.55 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$120.00 K
|
$744.00 K
|
$3.35 M
|
$270.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$2.18 M
|
$2.47 M
|
$1.55 M
|
$974.00 K
|
$1.93 M
|
$450.00 K
|
$214.00 K
|
$113.00 K
|
| EBITDA |
-$99.20 M |
-$112.30 M |
-$102.81 M |
-$85.09 M |
-$50.32 M |
-$31.88 M |
-$12.57 M |
-$5.44 M |
| EBITDA Ratio |
-2.71
|
-12.79
|
-8.29
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-2.77
|
-13.07
|
-8.41
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$12.39 M
|
$10.07 M
|
$3.29 M
|
$260.00 K
|
$801.00 K
|
$3.35 M
|
$260.00 K
|
-$4.00 K
|
| Income Before Tax |
-$88.98 M
|
-$104.70 M
|
-$101.07 M
|
-$85.81 M
|
-$52.24 M
|
-$32.33 M
|
-$12.52 M
|
-$5.56 M
|
| Income Before Tax Ratio |
-2.43
|
-11.92
|
-8.15
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$88.98 M
|
-$104.70 M
|
-$101.07 M
|
-$85.81 M
|
-$52.24 M
|
-$32.33 M
|
-$12.52 M
|
-$5.56 M
|
| Net Income Ratio |
-2.43
|
-11.92
|
-8.15
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.65 |
-2.38 |
-2.6 |
-2.34 |
-1.56 |
-1.59 |
-0.53 |
-0.24 |
| EPS Diluted |
-1.65 |
-2.38 |
-2.6 |
-2.34 |
-1.56 |
-1.59 |
-0.53 |
-0.24 |
| Weighted Average Shares Out |
$54.01 M
|
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$23.51 M
|
| Weighted Average Shares Out Diluted |
$54.01 M
|
$43.99 M
|
$38.90 M
|
$36.74 M
|
$33.49 M
|
$17.97 M
|
$23.51 M
|
$23.51 M
|
| Link |
|
|
|
|
|
|
|
|
